Needham Sticks to Their Hold Rating for Steris (STE)
In a report released today, Michael Matson from Needham maintained a Hold rating on Steris (STE). The company’s shares closed last Thursday at $194.73, close to its 52-week high of $196.55.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.9% and a 63.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Steris with a $200.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $196.55 and a one-year low of $105.69. Currently, Steris has an average volume of 400.8K.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STERIS Plc (Ireland) engages in the manufacture of medical and surgical equipment. The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.